MCID: PRS080
MIFTS: 25

Prostate Cancer, Hereditary, 7

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer, Hereditary, 7

MalaCards integrated aliases for Prostate Cancer, Hereditary, 7:

Name: Prostate Cancer, Hereditary, 7 57 13 73
Prostate Cancer Aggressiveness 57
Hpc7 57

Classifications:



External Ids:

OMIM 57 610321
MedGen 42 C1853195
UMLS 73 C1853195

Summaries for Prostate Cancer, Hereditary, 7

MalaCards based summary : Prostate Cancer, Hereditary, 7, also known as prostate cancer aggressiveness, is related to prostate cancer aggressiveness quantitative trait locus on chromosome 19 and prostate cancer. An important gene associated with Prostate Cancer, Hereditary, 7 is HPC7 (Prostate Cancer, Hereditary, 7). The drugs Selenium and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include prostate and bone.

Description from OMIM: 610321

Related Diseases for Prostate Cancer, Hereditary, 7

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 7

Clinical features from OMIM:

610321

Drugs & Therapeutics for Prostate Cancer, Hereditary, 7

Drugs for Prostate Cancer, Hereditary, 7 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
2
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
3
Olaparib Approved Phase 2 763113-22-0 23725625
4
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
5
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
6 Lycopene Approved, Investigational, Nutraceutical Phase 2 502-65-8 446925
7
Tocopherol Approved, Investigational, Nutraceutical Phase 2 1406-66-2 14986
8
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
9
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 6221 5280795
10
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
11 Antioxidants Phase 2
12 Bone Density Conservation Agents Phase 2
13 Carotenoids Phase 2
14 Ergocalciferols Phase 2
15 Micronutrients Phase 2
16 Protective Agents Phase 2
17 Radiation-Protective Agents Phase 2
18 Tocopherols Phase 2
19 Tocotrienols Phase 2
20 Trace Elements Phase 2
21 Vitamins Phase 2
22 Anti-Inflammatory Agents Phase 2
23 Antineoplastic Agents, Hormonal Phase 2
24 glucocorticoids Phase 2
25 Hormone Antagonists Phase 2
26 Hormones Phase 2
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
28 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
29 Calciferol Nutraceutical Phase 2
30 Tea Nutraceutical Phase 2
31 Tocotrienol Investigational, Nutraceutical Phase 2 6829-55-6
32 Vitamin D2 Nutraceutical Phase 2
33 Antibodies
34 Antigen-Antibody Complex
35 Immunoglobulins

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer Completed NCT00844792 Phase 2 Placebo
2 Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC Recruiting NCT03263650 Phase 2 Cabazitaxel;Carboplatin;Prednisone 5Mg;Olaparib
3 Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness Completed NCT03289130
4 Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer Completed NCT01780701
5 Development and Validation of Novel MRI Methods for the Detection of Prostate Cancer Aggressiveness Recruiting NCT02545881
6 MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness Recruiting NCT01464216
7 Advanced Magnetic Resonance Imaging (MRI) in Men With Suspected Prostate Cancer Recruiting NCT02745496 Not Applicable
8 Structural Network on Prostate Cancer in the French Greater West Region Recruiting NCT03214315
9 Biobank for African American Prostate Cancer Research in Florida Recruiting NCT03232411
10 Magnetic Resonance Spectroscopic Imaging of the Prostate at 3 Tesla Active, not recruiting NCT00588679 Not Applicable
11 Correlation Between iXip and Final Pathology Specimen From Radical Prostatectomy: a Multicenter Prospective Trial Not yet recruiting NCT03413007

Search NIH Clinical Center for Prostate Cancer, Hereditary, 7

Genetic Tests for Prostate Cancer, Hereditary, 7

Anatomical Context for Prostate Cancer, Hereditary, 7

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 7:

41
Prostate, Bone

Publications for Prostate Cancer, Hereditary, 7

Articles related to Prostate Cancer, Hereditary, 7:

(show all 38)
# Title Authors Year
1
The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. ( 28851363 )
2017
2
Normalized periprostatic fat MRI measurements can predict prostate cancer aggressiveness in men undergoing radical prostatectomy for clinically localised disease. ( 28680067 )
2017
3
Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians. ( 28039468 )
2017
4
T2-weighted MRI-derived textural features reflect prostate cancer aggressiveness: preliminary results. ( 27975146 )
2017
5
Observed correlation between the expression levels of catalytic subunit, CI^2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness. ( 27838142 )
2017
6
Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness. ( 27842896 )
2017
7
Trinucleotide repeat length in the first exon of the androgen receptor gene may be associated with prostate carcinogenesis and facilitate prediction of prostate cancer aggressiveness. ( 26895311 )
2016
8
Core 2 I^-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness. ( 26768364 )
2016
9
Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population. ( 26754263 )
2016
10
Association of genetic polymorphisms in the telomerase reverse transcriptase gene with prostate cancer aggressiveness. ( 25738283 )
2015
11
Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts. ( 25595908 )
2015
12
HES6 promotes prostate cancer aggressiveness independently of Notch signalling. ( 25864518 )
2015
13
Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. ( 25307492 )
2015
14
Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness. ( 25079439 )
2014
15
Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness. ( 25277178 )
2014
16
Novel nuclear localization of fatty acid synthase correlates with prostate cancer aggressiveness. ( 24907642 )
2014
17
Urinary nerve growth factor as an oncologic biomarker for prostate cancer aggressiveness. ( 24794250 )
2014
18
Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression. ( 23308245 )
2013
19
Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. ( 22549899 )
2013
20
Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T. ( 22843767 )
2012
21
Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness. ( 22025384 )
2012
22
Leptin increases prostate cancer aggressiveness. ( 21559935 )
2011
23
Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. ( 21135144 )
2011
24
The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. ( 21900597 )
2011
25
Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35. ( 20945404 )
2011
26
Contrast-enhanced harmonic ultrasonography for the assessment of prostate cancer aggressiveness: a preliminary study. ( 20046498 )
2010
27
Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. ( 20615892 )
2010
28
Cytokine genetic polymorphisms and prostate cancer aggressiveness. ( 19474090 )
2009
29
[Is power Doppler US a good predictor of prostate cancer aggressiveness]. ( 19421114 )
2009
30
Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness? ( 19627283 )
2009
31
Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. ( 19683746 )
2009
32
Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. ( 18519765 )
2008
33
Prostate specific antigen density correlates with features of prostate cancer aggressiveness. ( 17222621 )
2007
34
The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. ( 17698092 )
2007
35
Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. ( 12563560 )
2003
36
Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies. ( 12192601 )
2002
37
Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. ( 11535545 )
2001
38
Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. ( 8012984 )
1994

Variations for Prostate Cancer, Hereditary, 7

Expression for Prostate Cancer, Hereditary, 7

Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 7.

Pathways for Prostate Cancer, Hereditary, 7

GO Terms for Prostate Cancer, Hereditary, 7

Sources for Prostate Cancer, Hereditary, 7

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....